Tagi Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TAGI
TAGI has two approved drugs.
Drugs and US Patents for Tagi
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tagi | DEXMEDETOMIDINE HYDROCHLORIDE | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 212857-002 | Nov 23, 2020 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Tagi | METHAZOLAMIDE | methazolamide | TABLET;ORAL | 215615-001 | Oct 18, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Tagi | DEXMEDETOMIDINE HYDROCHLORIDE | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 212857-003 | Nov 23, 2020 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Tagi | DEXMEDETOMIDINE HYDROCHLORIDE | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 212857-001 | Nov 23, 2020 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Tagi | METHAZOLAMIDE | methazolamide | TABLET;ORAL | 215615-002 | Oct 18, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

